Clinical trials: Advanced Adenoma
Mesothelioma
Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
The primary objective of this trial is to determine the response rate of single agent zoledronic acid using a composite of criteria including the EORTC modified RECIST criteria and the EORTC tumor response criteria for 18F-FDG…
- Trial name
- UAB0901 (NCT01204203)
- Testing
- Zometa
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Alabama at Birmingham
Colorectal Adenoma, Colorectal Carcinoma
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps).
- Conditions
- Colorectal Adenoma, Colorectal Carcinoma, Colorectal Conventional Adenoma With Severe Dysplasia, Colorectal Tubulovillous Adenoma
- Trial name
- NCT02134925
- Testing
- Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms, Prostate Neoplasms
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.
- Conditions
- Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma
- Trial name
- NCT03685591
- Testing
- PF-06952229, Enzalutamide
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Pfizer
Locally Advanced or Metastatic Solid Tumor
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic…
- Trial name
- NCT03717415
- Testing
- Rebastinib, Carboplatin
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma.
- Conditions
- Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma
- Trial name
- NCT00459862
- Testing
- laboratory biomarker analysis, pazopanib hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of sapanisertib and ziv-aflibercept in treating patients with solid tumors that have come back (recurrent) and have spread to another place in the body (metastatic) or…
- Conditions
- Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma
- Trial name
- NCT02159989
- Testing
- Sapanisertib, Ziv-Aflibercept
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for…
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1
- Trial name
- NCT00454363
- Testing
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Malignant Mesothelioma
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Current therapies for advanced Mesothelioma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Mesothelioma.
- Trial name
- NCT00003508
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Burzynski Research Institute
Mesothelioma
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00101283
- Testing
- pemetrexed disodium, gemcitabine hydrochloride, carboplatin
- Where
- 115 sites in United States
- Volunteers
- 32 people
- Sponsor
- Eastern Cooperative Oncology Group
Pancreatic Neuroendocrine Tumor
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
This research study will test the safety of RAD001 in combination with temozolomide.
- Trial name
- NCT00576680
- Testing
- RAD001, Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Dana-Farber Cancer Institute
Risk for Colorectal Cancer
Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
The purpose of this study is to evaluate the immune response to MUC1 - poly-ICLC vaccine, an investigational or study vaccine. The MUC1 - poly-ICLC vaccine is being tested in persons with a history of advanced adenomatous polyps…
- Trial name
- NCT00773097
- Testing
- MUC1 - Poly ICLC
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Robert Schoen
Advanced Malignancies
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
- Trial name
- NCT03241173
- Testing
- INCAGN01949, Nivolumab, Ipilimumab
- Where
- 15 sites in United States
- Volunteers
- 52 people
- Sponsor
- Incyte Biosciences International Sàrl
Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers…
- Trial name
- NCT01466036
- Testing
- Cabozantinib
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Leukemia, Lung Cancer
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from…
- Conditions
- Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes
- Trial name
- NCT00398138
- Testing
- WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mesothelioma, Lung Cancer
Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)
The goal of this study is to assess the efficacy and safety of an oral investigational drug suberoylanilide hydroxamic acid (vorinostat, MK-0683) compared to placebo, in the treatment of participants with advanced malignant…
- Trial name
- NCT00128102
- Testing
- Vorinostat
- Volunteers
- 661 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Malignant Mesothelioma, Recurrent Malignant Mesothelioma
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
This phase II trial is studying how well sunitinib works in treating patients with advanced malignant mesothelioma of the pleura.
- Trial name
- NCT00392444
- Testing
- sunitinib malate
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
All Malignancies, Advanced Malignancies
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
The participants of this study will have advanced malignancies (also known as advanced cancer). The main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the tazemtostat (the study drug) when…
- Conditions
- All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor
- Trial name
- NCT04537715
- Testing
- Tazemetostat, Itraconazole, Rifampin
- Where
- 10 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Epizyme, Inc.
Carcinoid Tumors, Pancreatic NET
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
This is a prospective phase II open-label trial, stratifying patients equally into two cohorts consisting of carcinoid tumors and pancreatic neuroendocrine tumors (pNETs).
- Trial name
- NCT02575300
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute